Immunoprecise Antibodies Ltd

IPA12 Dec 2024
Healthcare
$0.39
-0.04 (-3.90%)
Lowest Today
$0.36
Highest Today
$0.39
Today’s Open
$0.39
Prev. Close
$0.4
52 Week High
$2.6
52 Week Low
$0.32
To Invest in Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd

Healthcare
IPA12 Dec 2024
-0.04 (-3.90%)
1M
3M
6M
1Y
5Y
Low
$0.36
Day’s Range
High
$0.39
0.36
52 Week Low
$0.32
52-Week Range
52 Week High
$2.6
0.32
1 Day
-
1 Week
+10.78%
1 month return
-5.81%
3 month return
-37.87%
6 month return
-60.19%
1 Year return
-64.03%
3 Years return
-91.92%
5 Years return
-
10 Years return
-
Institutional Holdings
Ingalls & Snyder LLC
5.41
Renaissance Technologies Corp
0.21
Bank of Montreal
0.2
BMO Capital Markets Corp.
0.2
Northern Trust Corp
0.18
CIBC World Markets Inc.
0.14
Gradient Capital Advisors, LLC
0.09

Market Status

Fundamentals
Market Cap
12.1 mln
PB Ratio
0.47
PE Ratio
0
Enterprise Value
19.65 mln
Total Assets
59.99 mln
Volume

Company Financials

Fund house & investment objective

Company Information
ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada.
Organisation
Immunoprecise Antibodies Ltd
Employees
72
Industry
Biotechnology
CEO
Dr. Jennifer Lynne Bath Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step